CA2202137A1 - Composition, device and method for enhanced electrotransport agent delivery - Google Patents

Composition, device and method for enhanced electrotransport agent delivery

Info

Publication number
CA2202137A1
CA2202137A1 CA002202137A CA2202137A CA2202137A1 CA 2202137 A1 CA2202137 A1 CA 2202137A1 CA 002202137 A CA002202137 A CA 002202137A CA 2202137 A CA2202137 A CA 2202137A CA 2202137 A1 CA2202137 A1 CA 2202137A1
Authority
CA
Canada
Prior art keywords
composition
agent delivery
electrotransport agent
electrotransport
enhanced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002202137A
Other languages
French (fr)
Other versions
CA2202137C (en
Inventor
J. Richard Gyory
Jane Yieh
James A. Huntington
Michael Cormier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
J. Richard Gyory
Jane Yieh
James A. Huntington
Michael Cormier
Alza Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J. Richard Gyory, Jane Yieh, James A. Huntington, Michael Cormier, Alza Corporation filed Critical J. Richard Gyory
Publication of CA2202137A1 publication Critical patent/CA2202137A1/en
Application granted granted Critical
Publication of CA2202137C publication Critical patent/CA2202137C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0412—Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

An electrotransport composition comprises at least one C2-C4 lower alcohol, unsaturated derivatives thereof, or mixtures thereof, and at least one C8-C14 higher alcohol, unsaturated derivatives thereof, or mixtures thereof. An electrotransport device and a method of increasing transdermal electrotransport flux utilize the composition of the invention for delivering pharmaceutically-acceptable agents across a body surface such as skin.
CA002202137A 1994-11-14 1995-11-01 Composition, device and method for enhanced electrotransport agent delivery Expired - Fee Related CA2202137C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US339,092 1994-11-14
US08/339,092 US5861439A (en) 1994-11-14 1994-11-14 Method for enhanced electrotransport agent delivery
PCT/US1995/014175 WO1996014870A1 (en) 1994-11-14 1995-11-01 Composition, device, and method for enhanced electrotransport agent delivery

Publications (2)

Publication Number Publication Date
CA2202137A1 true CA2202137A1 (en) 1996-05-23
CA2202137C CA2202137C (en) 2008-02-12

Family

ID=23327470

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002202137A Expired - Fee Related CA2202137C (en) 1994-11-14 1995-11-01 Composition, device and method for enhanced electrotransport agent delivery

Country Status (8)

Country Link
US (3) US5861439A (en)
EP (1) EP0792164B1 (en)
JP (1) JP3950169B2 (en)
AT (1) ATE258068T1 (en)
CA (1) CA2202137C (en)
DE (1) DE69532477T2 (en)
ES (1) ES2214513T3 (en)
WO (1) WO1996014870A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US6757560B1 (en) * 1999-04-09 2004-06-29 Novosis Pharma Ag Transdermal delivery system (TDS) with electrode network
US6647111B1 (en) * 1998-05-07 2003-11-11 Mci Communications Corporation System for executing advanced interactive voice response services using service-independent building blocks
CZ302498B6 (en) * 1999-11-15 2011-06-15 Pharma Mar, S. A. Pharmaceutical composition containing aplidine for treating cancer diseases
UA76718C2 (en) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Anticancer aplidine derivatives
GB0017999D0 (en) 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
NZ525196A (en) * 2000-10-12 2004-09-24 Pharma Mar S Treatment of cancers by aplidine in conjunction with a myoprotector
US7137975B2 (en) * 2001-02-13 2006-11-21 Aciont, Inc. Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent
DE10122324A1 (en) * 2001-05-08 2002-11-14 Philips Corp Intellectual Pty Flexible integrated monolithic circuit
DE10141650C1 (en) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
EP1435991B1 (en) * 2001-10-19 2008-10-15 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
WO2003090855A1 (en) * 2002-04-25 2003-11-06 Centre Pharmapeptides Apparatus and assembly for administering antimicrobial agent
ATE359802T1 (en) * 2002-10-04 2007-05-15 Photokinetix Inc PHOTOKINETIC DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES USING PULSATING INCOHERENT LIGHT.
ATE406171T1 (en) * 2003-03-12 2008-09-15 Dana Farber Cancer Inst Inc APLIDINE FOR THE TREATMENT OF MULTIPLE MYELOMA
US7706873B2 (en) * 2004-05-05 2010-04-27 Mario Ammirati System and method for controlled delivery of a therapeutic agent to a target location within an internal body tissue
WO2007139826A2 (en) * 2006-05-26 2007-12-06 Cara Therapeutics, Inc. Method for elevating prolactin in mammals
US20090137925A1 (en) * 2007-11-23 2009-05-28 Divya Cantor Impedance Spectroscopy Cervix Scanning Apparatus and Method

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250878A (en) * 1978-11-22 1981-02-17 Motion Control, Inc. Non-invasive chemical species delivery apparatus and method
CA1165240A (en) * 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
JPS5855411A (en) * 1981-09-28 1983-04-01 Nitto Electric Ind Co Ltd Base material composition and medicinal composition for external use
US4752612A (en) * 1983-07-01 1988-06-21 Nitto Electrical Industrial Co., Ltd. Method and percutaneously administering physiologically active agents using an alcohol adjuvant and a solvent
US4615699A (en) * 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
US4692328A (en) * 1985-09-24 1987-09-08 Dynatech Corporation Biologically useful polymer preparations
US4722726A (en) * 1986-02-12 1988-02-02 Key Pharmaceuticals, Inc. Method and apparatus for iontophoretic drug delivery
EP0267617B1 (en) * 1986-11-14 1992-06-24 Theratech, Inc. Penetration enhancement with binary system of cell envelope disordering compounds and lower alcohols
US5080646A (en) * 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
JPS6425717A (en) * 1987-05-08 1989-01-27 Eastman Kodak Co Method and apparatus for preventing organic nitric acid ester resistance
DE3819842C1 (en) * 1988-03-23 1989-12-21 Karl Heinz Dr. 7100 Heilbronn De Thiel
US5162042A (en) * 1988-07-05 1992-11-10 Alza Corporation Electrotransport transdermal system
US5147296A (en) * 1988-10-03 1992-09-15 Alza Corporation Membrane for electrotransport transdermal drug delivery
US4927408A (en) * 1988-10-03 1990-05-22 Alza Corporation Electrotransport transdermal system
US5169382A (en) * 1988-10-03 1992-12-08 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5240995A (en) * 1989-02-09 1993-08-31 Alza Corporation Electrotransport adhesive
US5234992A (en) * 1989-02-09 1993-08-10 Alza Corporation Electrotransport adhesive
US5023085A (en) * 1989-11-29 1991-06-11 Pfizer Inc. Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
US5125894A (en) * 1990-03-30 1992-06-30 Alza Corporation Method and apparatus for controlled environment electrotransport
US5149719A (en) * 1990-04-27 1992-09-22 Minnesota Mining And Manufacturing Company Composition for transdermal penetration of medicaments
US5221254A (en) * 1991-04-02 1993-06-22 Alza Corporation Method for reducing sensation in iontophoretic drug delivery
US5356632A (en) * 1991-09-12 1994-10-18 S.I. Scientific Innovations Ltd. Transdermal drug delivery device
US5312439A (en) * 1991-12-12 1994-05-17 Loeb Gerald E Implantable device having an electrolytic storage electrode
ATE169826T1 (en) * 1992-01-21 1998-09-15 Macrochem Corp IONTOPHORETIC IMPROVED DRUG DELIVERY
US5240495A (en) * 1992-04-02 1993-08-31 Cornell Research Foundation, Inc. In situ formation of metal-ceramic oxide microstructures
US5380271A (en) * 1992-09-24 1995-01-10 Alza Corporation Electrotransport agent delivery device and method
US5298017A (en) * 1992-12-29 1994-03-29 Alza Corporation Layered electrotransport drug delivery system
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery

Also Published As

Publication number Publication date
EP0792164B1 (en) 2004-01-21
WO1996014870A1 (en) 1996-05-23
ATE258068T1 (en) 2004-02-15
EP0792164A1 (en) 1997-09-03
CA2202137C (en) 2008-02-12
JP3950169B2 (en) 2007-07-25
DE69532477D1 (en) 2004-02-26
DE69532477T2 (en) 2004-11-25
US5883135A (en) 1999-03-16
US5861439A (en) 1999-01-19
US6083190A (en) 2000-07-04
ES2214513T3 (en) 2004-09-16
JPH10508850A (en) 1998-09-02

Similar Documents

Publication Publication Date Title
CA2202137A1 (en) Composition, device and method for enhanced electrotransport agent delivery
EP1857113A3 (en) USE OF ANTIFUNGAL AGENTS FOR THE TOPICAL TREATMENT OF asthma
AU7323794A (en) Method and device for providing nicotine replacement therapy transdermally/transbuccally
NZ232078A (en) Delivery device powered by a hydrogel
ES2092876T3 (en) DEPIGMENTING COMPOSITION FOR THE SIMULTANEOUS TREATMENT OF DEEP AND SURFACE LAYERS OF THE SKIN.
AU5106890A (en) Device for the transdermal delivery of nicotine
IL124629A0 (en) Transdermal device for the delivery of flurbiprofen
AU629777B2 (en) Blocking agents of edrf effect or formation for the treatment of shock
GB9027683D0 (en) Two-part device for the controlled delivery of an active ingredient
CA2010218A1 (en) Therapeutic system for the retarded and controlled transdermal or transmucous administration of active substances
EP0619983A3 (en) Surgical needle and apparatus for grinding the same.
AU5852794A (en) Sterilization devices, sporidical compositions, sterilization methods, and devices for reducing surface tension
EP0640097A4 (en) Compositions and methods for vaccination against coronaviruses.
EP0639076A4 (en) Use of guanylate cyclase inhibitors in the treatment of shock.
AU7227394A (en) Method for surface treatment, means for carrying out the method and the use thereof
HK1001286A1 (en) Benzopyrans and their use as therapeutic agents.
CA2135709A1 (en) Melatonin derivatives for use in treating sleep disorders
IT1274859B (en) METHOD AND DEVICE FOR THE PNEUMATIC SUPPLY OF CIGARETTE PACKAGES.
ZA935154B (en) Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions
HU9401833D0 (en) Use of renin inhibitors for the treatment of glaucoma
AU3737289A (en) Agent for treating pancreatitis or the like
CA2197176A1 (en) Use of selegiline for the treatment of epileptic disorders
EP0610669A3 (en) Apparatus for treating parts of the body by vibration.
IL104756A0 (en) Composition for the treatment of glaucoma
WO1993006813A3 (en) Hair treatment composition

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed